Scopus BioPharma Inc.

Equities

SCPS

US8091711015

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:47:33 10/07/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-99.50%		0.00%	-99.54%

2023	Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	CI
2023	Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Scopus Biopharma Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020

January 29, 2021 at 02:04 am IST

Scopus BioPharma Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 875,466 compared to USD 797,220 a year ago. Net loss was USD 1.159 million compared to USD 797,220 a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.06 a year ago. For the nine months, operating loss was USD 9.441 million compared to USD 1.726 million a year ago. Net loss was USD 9.811 million compared to USD 1.726 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.15 a year ago.

Latest news about Scopus BioPharma Inc.

Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	07/11	CI
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	14/23/14	CI
Scopus BioPharma Inc.(NasdaqCM:SCPS) dropped from S&P TMI Index	21/22/21	CI
Scopus BioPharma Inc.(NasdaqGM:SCPS) dropped from NASDAQ Composite Index	16/22/16	CI
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower	15/22/15	MT
Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move Lower	15/22/15	MT
Top Premarket Gainers	15/22/15	MT
Scopus BioPharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Top Premarket Decliners	11/22/11	MT
Scopus BioPharma Inc. Announces Resignation of Paul Hopper from Board of Directors	21/22/21	CI
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	20/22/20	CI
Scopus Biopharma Inc. Announces Resignation of Ashish Sanghrajka from the Board of Directors with Effect from May 11, 2022	14/22/14	CI
Scopus BioPharma Inc. Appoints Raphael Hofstein to its Board of Directors	05/22/05	CI
Scopus Biopharma Inc. Announces Board Resignations	30/22/30	CI
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Scopus BioPharma Announces the Final Results	10/22/10	CI
Scopus BioPharma Inc. Announces Board Appointments	06/22/06	CI
Declaration of Preliminary Voting Results by Scopus BioPharma	28/21/28	CI
Scopus BioPharma Sends Letter to its Shareholders	17/21/17	CI
Scopus BioPharma Sends Letter to its Shareholders	08/21/08	CI

Chart Scopus BioPharma Inc.

Duration

Period

More charts

Company Profile

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Companyâs Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCOPUS BIOPHARMA INC.	-99.54%	42
VERTEX PHARMACEUTICALS INCORPORATED	+20.23%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.18%	12TCr
ARGENX SE	+25.44%	2.77TCr
BIONTECH SE	-18.50%	2.03TCr
GENMAB A/S	-15.17%	1.68TCr
BEIGENE, LTD.	-15.72%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+12.70%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+56.56%	1.44TCr

Bio Therapeutic Drugs